IL112261A - RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE - Google Patents

RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE

Info

Publication number
IL112261A
IL112261A IL11226195A IL11226195A IL112261A IL 112261 A IL112261 A IL 112261A IL 11226195 A IL11226195 A IL 11226195A IL 11226195 A IL11226195 A IL 11226195A IL 112261 A IL112261 A IL 112261A
Authority
IL
Israel
Prior art keywords
sequence
compound
momlv
hiv tat
hiv
Prior art date
Application number
IL11226195A
Other languages
English (en)
Other versions
IL112261A0 (en
Original Assignee
Gene Shears Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/178,082 external-priority patent/US5712384A/en
Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd
Publication of IL112261A0 publication Critical patent/IL112261A0/xx
Publication of IL112261A publication Critical patent/IL112261A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL11226195A 1994-01-05 1995-01-05 RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE IL112261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/178,082 US5712384A (en) 1994-01-05 1994-01-05 Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US08/310,259 US6114167A (en) 1994-01-05 1994-09-21 Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence

Publications (2)

Publication Number Publication Date
IL112261A0 IL112261A0 (en) 1995-03-30
IL112261A true IL112261A (en) 2005-08-31

Family

ID=26873946

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11226195A IL112261A (en) 1994-01-05 1995-01-05 RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE

Country Status (14)

Country Link
EP (2) EP0753062A4 (no)
JP (1) JP3691849B2 (no)
CN (1) CN1267552C (no)
AT (1) ATE320487T1 (no)
AU (1) AU698730B2 (no)
CA (1) CA2180358A1 (no)
DE (1) DE69534864T2 (no)
DK (1) DK1298208T3 (no)
ES (1) ES2260376T3 (no)
IL (1) IL112261A (no)
NO (1) NO319376B1 (no)
NZ (1) NZ278432A (no)
PT (1) PT1298208E (no)
WO (1) WO1995018854A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0865282A4 (en) * 1995-08-25 2002-01-16 Univ California Chimeric antiviral agents that contain REV-binding nucleic acids
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
EP0871757B1 (en) * 1995-11-28 2003-03-12 The Johns Hopkins University School Of Medicine Conditionally replicating viral vectors and their use
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ATE526406T1 (de) 1998-03-20 2011-10-15 Commw Scient Ind Res Org Kontrolle der genexpression
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US7345025B2 (en) 2001-07-10 2008-03-18 Johnson & Johnson Research Pty. Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CN102841007A (zh) * 2012-09-05 2012-12-26 福建省农业科学院畜牧兽医研究所 一种便于鸭精子计数的精液稀释液及其使用方法
CN113549641B (zh) * 2021-06-29 2023-12-22 复旦大学 一种核酶介导的多顺反子载体及其构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
CA2107789A1 (en) * 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
CA2154363A1 (en) * 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication

Also Published As

Publication number Publication date
JP3691849B2 (ja) 2005-09-07
EP1298208A3 (en) 2004-01-07
NO962826L (no) 1996-08-27
CN1145638A (zh) 1997-03-19
DK1298208T3 (da) 2006-07-24
AU1391295A (en) 1995-08-01
AU698730B2 (en) 1998-11-05
CA2180358A1 (en) 1995-07-13
PT1298208E (pt) 2006-10-31
EP0753062A4 (en) 1999-10-20
DE69534864D1 (de) 2006-05-11
ATE320487T1 (de) 2006-04-15
CN1267552C (zh) 2006-08-02
IL112261A0 (en) 1995-03-30
NO319376B1 (no) 2005-07-25
DE69534864T2 (de) 2007-02-22
ES2260376T3 (es) 2006-11-01
WO1995018854A1 (en) 1995-07-13
EP0753062A1 (en) 1997-01-15
EP1298208B1 (en) 2006-03-15
NO962826D0 (no) 1996-07-04
JPH09508004A (ja) 1997-08-19
NZ278432A (en) 1998-06-26
EP1298208A2 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
IL112261A (en) RIBOZYMES TARGETING THE MoMLV PSI PACKAGING SEQUENCE AND THE HIV TAT SEQUENCE
WO1996019568A3 (en) Stabilized ribozyme analogs
WO1998044097A3 (en) Method for enhancing expression of a foreign or endogenous gene product in plants
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
CA2340416A1 (en) Co-lyophilized complex of a nucleic acid vector and a formulating agent
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
WO2005049844A3 (en) Vectors, mutant viruses and methods for generating mutant viruses
ZA954451B (en) The cytoplasmic inhibition of gene expression
WO1998056937A3 (en) Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
IL80407A0 (en) Novel plant plasmid vector
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
DK0630409T3 (da) Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV
EP0816487A4 (en) CELL THAT PRODUCES RECOMBINANT HIV
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
DK0632026T3 (da) Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
IL117194A0 (en) Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
EP0915156A4 (en) GENE ASSOCIATED WITH IgA GLOMERULONEPHRITIS
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
GB9409156D0 (en) Therapeutic compounds
FR2721617B1 (fr) Fragments d'acides nucléiques, dérivés du génome de Mycobacterium xenopi et leurs applications.
MX9708943A (es) Genes de polifenol oxidasa de la lengua y platano.
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees